This guidance updates and replaces NICE's technology appraisal guidance 212 on bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results